A Concise Review on the Use of Mesenchymal Stem Cells in Cell Sheet-Based Tissue Engineering with Special Emphasis on Bone Tissue Regeneration

Yörükoğlu, Ali Çağdaş; Kiter, Esat; Akkaya, Semih; Şatıroğlu-Tufan, N. Lale; Tufan, A. Çevik

doi:10.1155/2017/2374161

Cited by 68 publications

(59 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The grafting of a tissue‐engineered construct seeded with adult mesenchymal stem cells (MSCs) into injured and ischemic tissues has emerged in the past decade as a potential therapeutic option for bone repair and regeneration . The success of such an approach is directly conditioned by the establishment of a fully functional vascular network within the grafted tissue construct to allow its survival.…”

Section: Introductionmentioning

confidence: 99%

Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects

Novais

Lesieur

Sadoine

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

The craniofacial area is prone to trauma or pathologies often resulting in large bone damages. One potential treatment option is the grafting of a tissue‐engineered construct seeded with adult mesenchymal stem cells (MSCs). The dental pulp appears as a relevant source of MSCs, as dental pulp stem cells display strong osteogenic properties and are efficient at bone formation and repair. Fibroblast growth factor‐2 (FGF‐2) and/or hypoxia primings were shown to boost the angiogenesis potential of dental pulp stem cells from human exfoliated deciduous teeth (SHED). Based on these findings, we hypothesized here that these primings would also improve bone formation in the context of craniofacial bone repair. We found that both hypoxic and FGF‐2 primings enhanced SHED proliferation and osteogenic differentiation into plastically compressed collagen hydrogels, with a much stronger effect observed with the FGF‐2 priming. After implantation in immunodeficient mice, the tissue‐engineered constructs seeded with FGF‐2 primed SHED mediated faster intramembranous bone formation into critical size calvarial defects than the other groups (no priming and hypoxia priming). The results of this study highlight the interest of FGF‐2 priming in tissue engineering for craniofacial bone repair. Stem Cells Translational Medicine 2019;8:844&857

show abstract

Section: Introductionmentioning

confidence: 99%

Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects

Novais

Lesieur

Sadoine

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The cell sheet technique is based on implantation of cells grown as single or multiple layers together with their secreted extracellular matrix (ECM), as opposed to conventional single‐cell suspensions. Proposed advantages of this technique include preservation of the cell‐to‐cell connections and ECM components along with a high cell‐seeding efficacy (Yorukoglu, Kiter, Akkaya, Satiroglu‐Tufan, & Tufan, ). Superior NBF after 4 months and comparable volumetric stability of augmented sites after 6–12 months were observed in the POC‐seeded AB (+PRP) grafts compared to conventional AB (+PRP) grafts (Nagata et al., ; Ogawa et al., ).…”

Section: Discussionmentioning

confidence: 99%

Cell therapy for orofacial bone regeneration: A systematic review and meta‐analysis

Shanbhag

Suliman

Pandis

et al. 2019

J Clinic Periodontology

View full text Add to dashboard Cite

Aim The objective of the present review was to answer the focused question: what is the effect of cell therapy in terms of orofacial bone regeneration compared to grafting with only biomaterial scaffolds and/or autogenous bone? Methods Electronic databases were searched for relevant controlled clinical and pre‐clinical (large‐animal) studies. Separate meta‐analyses of quantitative data regarding histological or radiographic new bone formation were performed. Results Forty‐seven eligible clinical and 57 pre‐clinical studies were included. Clinical studies were categorized based on the use of “minimally manipulated” whole tissues (e.g., bone marrow) or ex vivo expanded cells from “uncommitted” (bone marrow, adipose tissue) or “committed” sources (periosteum, bone). Based on limited and heterogeneous clinical evidence, implantation of cells (mostly whole bone marrow), in combination with biomaterial scaffolds results in bone regeneration which is (a) superior compared to implantation of scaffolds alone in sinus and horizontal ridge augmentation, and (b) comparable to autogenous bone in alveolar cleft repair. Conclusions Although current evidence points to the benefits of cell therapy in certain clinical indications, it is unclear whether the use of ex vivo expanded cells, either uncommitted or committed, is superior to whole tissue fractions in terms of bone regeneration. The relatively larger effect sizes in favour of cell therapy observed in pre‐clinical studies are diminished in clinical trials. Future controlled studies should include cost‐effectiveness analyses to guide clinical decision‐making.

show abstract

“…Examples on MSC-delivered genes are SDF-1 to ameliorate MI and ischemic brain injury (Penn and Khalil, 2008), glucagon-like peptide-1 to reduce amyloid deposition in Alzheimer's brains (Klinge et al, 2011), and IL-10 to restrain collagen-induced arthritis (Choi et al, 2008). Architectural MSC engineering involves cell culturing to obtain cellular sheets which can be further maintained in organspecific stimulating media or assembled onto organ scaffolds to restore injured or defective tissue [e.g., bone regeneration (Yorukoglu et al, 2017) and spinal cord injury (Zeng et al, 2011) applications].…”

Section: Regenerative Medicinementioning

confidence: 99%

Mesenchymal Stem Cells Beyond Regenerative Medicine

Shammaa

El-Kadiry

Abusarah

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are competent suitors of cellular therapy due to their therapeutic impact on tissue degeneration and immune-based pathologies. Additionally, their homing and immunomodulatory properties can be exploited in cancer malignancies to transport pharmacological entities, produce anti-neoplastic agents, or induce antitumor immunity. Herein, we create a portfolio for MSC properties, showcasing their distinct multiple therapeutic utilities and successes/challenges thereof in both animal studies and clinical trials. We further highlight the promising potential of MSCs not only in cancer management but also in instigating tumor-specific immunityi.e., cancer vaccination. Finally, we reflect on the possible reasons impeding the clinical advancement of MSC-based cancer vaccines to assist in contriving novel methodologies from which a therapeutic milestone might emanate.

show abstract

A Concise Review on the Use of Mesenchymal Stem Cells in Cell Sheet-Based Tissue Engineering with Special Emphasis on Bone Tissue Regeneration

Cited by 68 publications

References 103 publications

Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects

Priming Dental Pulp Stem Cells from Human Exfoliated Deciduous Teeth with Fibroblast Growth Factor-2 Enhances Mineralization Within Tissue-Engineered Constructs Implanted in Craniofacial Bone Defects

Cell therapy for orofacial bone regeneration: A systematic review and meta‐analysis

Mesenchymal Stem Cells Beyond Regenerative Medicine

Contact Info

Product

Resources

About